ReviewPharmaceutics2022
General Characteristics, Biomedical and Dental Application, and Usage of Chitosan in the Treatment of Temporomandibular Joint Disorders: A Narrative Review.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Anionic Polysaccharides: Promising 3D Bioink Candidates for Tissue Engineering.Bioengineering (Basel, Switzerland) · 2026Review
- Recent Use of Hyaluronic Acid in Dental Medicine.Materials (Basel, Switzerland) · 2025Review
- Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity.Pharmaceutics · 2024Review
- Analysis of the Curative Effect of Temporomandibular Joint Disc Release and Fixation Combined with Chitosan Injection in the Treatment of Temporomandibular Joint Osteoarthrosis.Journal of clinical medicine · 2023Article
- Chitosan Based Materials in Cosmetic Applications: A Review.Molecules (Basel, Switzerland) · 2023Review
- Novel Epigenetic Modulation Chitosan-Based Scaffold as a Promising Bone Regenerative Material.Cells · 2022Article
- Evaluation of the efficacy of platelet rich fibrin (I-PRF) intra-articular injections in the management of internal derangements of temporomandibular joints - a controlled preliminary prospective clinical study.BMC musculoskeletal disorders · 2022Article
- Drug delivery systems for treatment of temporomandibular joint osteoarthritis.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this narrative review was to present research investigating chitosan, including its general characteristics, properties, and medical and dental applications, and finally to present the current state of knowledge regarding the efficacy of chitosan in the treatment of temporomandibular disorders (TMDs) based on the literature. The PICO approach was used for the literature search strategy. The PubMed database was analyzed with the following keywords: ("chitosan"[MeSH Terms] OR "chitosan"[All Fields] OR "chitosans"[All Fields] OR "chitosan s"[All Fields] OR "chitosane"[All Fields]) AND ("temporomandibular joint"[MeSH Terms] OR ("tem-poromandibular"[All Fields] AND "joint"[All Fields]) OR "temporomandibular joint"[All Fields] OR ("temporomandibular"[All Fields] AND "joints"[All Fields]) OR "temporo-mandibular joints"[All Fields]). After screening 8 results, 5 studies were included in this review. Chitosan presents many biological properties and therefore it can be widely used in several branches of medicine and dentistry. Chitosan promotes wound healing, helps to control bleeding, and is used in wound dressings, such as sutures and artificial skin. Apart from its antibacterial property, chitosan has many other properties, such as antifungal, mucoadhesive, anti-inflammatory, analgesic, antioxidant, antihyperglycemic, and antitumoral properties. Further clinical studies assessing the efficacy of chitosan in the treatment of TMD are required. According to only one clinical study, chitosan was effective in the treatment of TMD; however, better clinical results were obtained with platelet-rich plasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.